Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) saw strong trading volume on Tuesday . 26,087,509 shares were traded during trading, an increase of 16% from the previous session's volume of 22,576,836 shares.The stock last traded at $11.00 and had previously closed at $10.53.
Wall Street Analyst Weigh In
Several research firms recently weighed in on RXRX. Needham & Company LLC restated a "buy" rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a report on Thursday, February 6th. KeyCorp cut their price target on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating on the stock in a report on Wednesday, January 8th.
Get Our Latest Research Report on Recursion Pharmaceuticals
Recursion Pharmaceuticals Trading Down 10.3 %
The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. The stock has a market capitalization of $3.63 billion, a PE ratio of -6.07 and a beta of 0.86. The stock's 50 day simple moving average is $7.52 and its two-hundred day simple moving average is $7.00.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Allspring Global Investments Holdings LLC purchased a new stake in shares of Recursion Pharmaceuticals during the 3rd quarter valued at approximately $25,000. Decker Retirement Planning Inc. bought a new stake in Recursion Pharmaceuticals during the 4th quarter worth approximately $26,000. Private Trust Co. NA bought a new stake in Recursion Pharmaceuticals during the 4th quarter worth approximately $27,000. GAMMA Investing LLC increased its holdings in Recursion Pharmaceuticals by 1,979.2% during the 4th quarter. GAMMA Investing LLC now owns 5,198 shares of the company's stock worth $35,000 after acquiring an additional 4,948 shares during the period. Finally, Farther Finance Advisors LLC increased its holdings in Recursion Pharmaceuticals by 176.9% during the 3rd quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company's stock worth $42,000 after acquiring an additional 4,091 shares during the period. 89.06% of the stock is currently owned by hedge funds and other institutional investors.
Recursion Pharmaceuticals Company Profile
(
Get Free Report)
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
Featured Articles
Before you consider Recursion Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recursion Pharmaceuticals wasn't on the list.
While Recursion Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
